Sunday 29 October 2017

Transgene: First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma

http://markets.businessinsider.com/news/stocks/transgene-first-patient-treated-in-a-phase-1-2a-trial-oncovirac-of-novel-oncolytic-virus-tg6002-in-recurrent-glioblastoma-1005718380
Posted by at
Labels: , , ,

1 comment:

  1. Matjaz29 October 2017 at 09:37

    Nice, on the paper it is comparable to Toca511, hope it is also comparable in outcomes. I think Toca511 trials weren't accessible in Europe, so this will come handy for european patients

    ReplyDelete

Subscribe to: Post Comments (Atom)